Management of Patients with Newly Diagnosed Diabetic Mellitus: Ophthalmologic Outcomes in Intensive versus Conventional Glycemic Control

References

• Pettitt DJ, Okada Wollitzer A, Jovanovic L, et al. Decreasing the risk of diabetic retinopathy in a study of case management: the California medi-cal type 2 diabetes study. Diabetes Care. 2005;28:2819–2822. doi:10.2337/diacare.28.12.2819
   Web of Science ®Google Scholar
• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet (London, England). 2010;376:124–136. doi:10.1016/s0140-6736(09)62124-3
   PubMed Web of Science ®Google Scholar
• Papatheodorou K, Papanas N, Banach M, et al. Complications of diabetes 2016. J Diabetes Res. 2016;2016:6989453. doi:10.1155/2016/6989453
   PubMed Web of Science ®Google Scholar
• Schlienger JL. [Type 2 diabetes complications]. Presse medicale (Paris, France: 1983). 2013;42:839–848. French. doi:10.1016/j.lpm.2013.02.313
   PubMed Web of Science ®Google Scholar
• Melendez-Ramirez LY, Richards RJ, Cefalu WT. Complications of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39:625–640. doi:10.1016/j.ecl.2010.05.009
   PubMed Web of Science ®Google Scholar
• Pearce I, Simó R, Lövestam-Adrian M, et al. Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review. Diabetes Obes Metab. 2019;21:467–478. doi:10.1111/dom.13550
   PubMed Web of Science ®Google Scholar
• Kotlarsky P, Bolotin A, Dorfman K, et al. Link between retinopathy and nephropathy caused by complications of diabetes mellitus type 2. Int Ophthalmol. 2015;35:59–66. doi:10.1007/s10792-014-0018-6
   Web of Science ®Google Scholar
• El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, et al. Retinopathy as a predictor of other diabetic complications. Int Ophthalmol. 2001;24:1–11. doi:10.1023/a:1014409829614
   Google Scholar
• Kramer CK, Retnakaran R. Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Med. 2013;30:1333–1341. doi:10.1111/dme.12296
   PubMed Web of Science ®Google Scholar
• Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859–1868. doi:10.1016/j.ophtha.2008.08.023
   PubMed Web of Science ®Google Scholar
• Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156–163. doi:10.1007/s001250051594
   PubMed Web of Science ®Google Scholar
• Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16. doi:10.2337/dc13-2112
   PubMed Web of Science ®Google Scholar
• Azad N, Agrawal L, Emanuele NV, et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2014;57:1124–1131. doi:10.1007/s00125-014-3199-7
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559. doi:10.1056/NEJMoa0802743
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S66–S76. doi:10.2337/dc20-S006
   PubMed Web of Science ®Google Scholar
• Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabetic Med. 2008;25:1151–1156. doi:10.1111/j.1464-5491.2008.02565.x
   PubMed Web of Science ®Google Scholar
• Testa MA, Puklin JE, Sherwin RS, et al. Clinical predictors of retinopathy and its progression in patients with type I diabetes during CSII or conventional insulin treatment. Diabetes. 1985;34(Suppl 3):61–68. doi:10.2337/diab.34.3.s61
   PubMed Web of Science ®Google Scholar
• The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. JAMA. 1988;260:37–41. doi:10.1001/jama.1988.03410010045032
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 1995;113:36–51. doi:10.1001/archopht.1995.01100010038019
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647–661. doi:10.1016/s0161-6420(95)30973-6
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874–886. doi:10.1001/archopht.116.7.874
   PubMed Web of Science ®Google Scholar
• Aiello LP, Ayala AR, Antoszyk AN, et al. Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits on glycemic control: a randomized clinical trial. JAMA Ophthalmol. 2015;133:888–896. doi:10.1001/jamaophthalmol.2015.1312
   PubMed Web of Science ®Google Scholar
• Brinchmann-Hansen O, Dahl-Jørgensen K, Sandvik L, et al. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ (Clinical Research Ed). 1992;304:19–22. doi:10.1136/bmj.304.6818.19
   PubMed Web of Science ®Google Scholar
• Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–244. doi:10.1056/NEJMoa1001288
   PubMed Web of Science ®Google Scholar
• Crofford OB. Diabetes control and complications. Annu Rev Med. 1995;46:267–279. doi:10.1146/annurev.med.46.1.267
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. J Pediatr. 1994;125:177–188. doi:10.1016/s0022-3476(94)70190-3
   PubMed Web of Science ®Google Scholar
• Lachin JM, Orchard TJ, Nathan DM. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:39–43. doi:10.2337/dc13-2116
   PubMed Web of Science ®Google Scholar
• White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the diabetes control and complications trial. Arch Ophthalmol. 2008;126:1707–1715. doi:10.1001/archopht.126.12.1707
   PubMed Web of Science ®Google Scholar
• Kilpatrick ES, Rigby AS, Atkin SL, et al. Does severe hypoglycaemia influence microvascular complications in Type 1 diabetes? An analysis of the Diabetes Control and Complications Trial database. Diabetic Med. 2012;29:1195–1198. doi:10.1111/j.1464-5491.2012.03612.x
   Web of Science ®Google Scholar
• Lachin JM, Genuth S, Cleary P, et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–389. doi:10.1056/nejm200002103420603
   PubMed Web of Science ®Google Scholar
• Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. doi:10.1056/nejm199309303291401
   PubMed Web of Science ®Google Scholar
• Service FJ, O’Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia. 2001;44:1215–1220. doi:10.1007/s001250100635
   PubMed Web of Science ®Google Scholar
• Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci. 1998;39:233–252.
   PubMed Web of Science ®Google Scholar
• Emanuele N, Klein R, Abraira C, et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care. 1996;19:1375–1381. doi:10.2337/diacare.19.12.1375
   PubMed Web of Science ®Google Scholar
• Henricsson M, Berntorp K, Berntorp E, et al. Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Relation to IGF-1 and hemostatic variables. Diabetes Care. 1999;22:1944–1949. doi:10.2337/diacare.22.12.1944
   Web of Science ®Google Scholar
• Molyneaux LM, Constantino MI, McGill M, et al. Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract. 1998;42:77–83. doi:10.1016/s0168-8227(98)00095-3
   PubMed Web of Science ®Google Scholar
• Kayashima T, Yamaguchi K, Konno Y, et al. Effects of early introduction of intensive insulin therapy on the clinical course in non-obese NIDDM patients. Diabetes Res Clin Pract. 1995;28:119–125. doi:10.1016/0168-8227(95)01066-m
   Web of Science ®Google Scholar
• Lachin JM, White NH, Hainsworth DP, et al. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64:631–642. doi:10.2337/db14-0930
   PubMed Web of Science ®Google Scholar
• Hollander P, Cooper J, Bregnhøj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30:1976–1987. doi:10.1016/j.clinthera.2008.11.001
   PubMed Web of Science ®Google Scholar
• Jingi AM, Tankeu AT, Ateba NA, et al. Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis. BMC Endocr Disord. 2017;17:63. doi:10.1186/s12902-017-0213-3
   Web of Science ®Google Scholar
• Bain SC, Klufas MA, Ho A, et al. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diabetes Obes Metab. 2019;21:454–466. doi:10.1111/dom.13538
   PubMed Web of Science ®Google Scholar
• Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet (London, England). 2007;370:1687–1697. doi:10.1016/s0140-6736(07)61607-9
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College Of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26:107–139. doi:10.4158/cs-2019-0472
   PubMed Web of Science ®Google Scholar
• Anderson RT, Narayan KM, Feeney P, et al. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care. 2011;34:807–812. doi:10.2337/dc10-1926
   Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139. doi:10.1056/NEJMoa0808431
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20:889–897. doi:10.1111/dom.13172
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119:351–357. doi:10.1161/circulationaha.108.191305
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. doi:10.1056/NEJMoa0806470
   PubMed Web of Science ®Google Scholar
• Testa R, Bonfigli AR, Prattichizzo F, et al. The “metabolic memory” theory and the early treatment of hyperglycemia in prevention of diabetic complications. Nutrients. 2017;9:437. doi:10.3390/nu9050437
   PubMed Web of Science ®Google Scholar
• Knickelbein JE, Abbott AB, Chew EY. Fenofibrate and diabetic retinopathy. Curr Diab Rep. 2016;16:90. doi:10.1007/s11892-016-0786-7
   Web of Science ®Google Scholar
• Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye study. Ophthalmology. 2014;121:2443–2451. doi:10.1016/j.ophtha.2014.07.019
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of clinical epidemiology.. 2009;62(10)
   Google Scholar